Teleflex

What Teleflex does

Teleflex Incorporated (NYSE: TFX) is a global medical technology company founded in 1943 and headquartered in Wayne, Pennsylvania, with 10,000+ employees, manufacturing and R&D operations in Morrisville (NC) and Reading (PA), and commercial reach across the Americas, EMEA, and Asia Pacific. The company designs, manufactures, and sells a diversified portfolio of medical devices organized around Vascular Access (Arrow-branded CVCs, PICCs, antimicrobial catheters, and VPS tip-positioning systems), Emergency Medicine (EZ-IO intraosseous access, QuikClot hemostatic dressings), Interventional Cardiology/Radiology (MANTA vascular closure, Freesolve resorbable magnesium scaffold, GuideLiner catheters, IABP, plus the newly acquired BIOTRONIK coronary/peripheral portfolio), Surgical (Weck ligation, EFx Shield fascial closure, MiniLap), Urology (UroLift, Rüsch intermittent catheters, Barrigel rectal spacer), Anesthesia (LMA airways), and Military/Federal channels. Core technologies include antimicrobial catheter surface treatments (Arrowg+ard), Doppler/ECG-based catheter tip positioning (VPS), intraosseous vascular access (EZ-IO), bioresorbable magnesium alloy scaffolds (Freesolve/DREAMS 3G), and large-bore vascular closure (MANTA).

Teleflex generates revenue primarily through one-time hardware sales of capital equipment and consumable medical devices to hospitals, healthcare systems, and emergency/critical care providers, supplemented by service contracts and parts. Pricing is not publicly disclosed and is delivered through quote-based direct sales, the myTeleflex.com e-commerce portal, medical product distributors and wholesalers, GPO contracts, and specialized federal/military distributors. Customer segments span acute care hospitals, emergency departments and EMS, federal/military medical facilities (including VA and DoD), and ambulatory/alternate-site providers. FY2025 GAAP revenue from continuing operations reached $1,992.7 million, up 17.2% year-over-year, with Q1 2026 at $548.3 million.

Teleflex is mid-transformation: in 2025 it completed the acquisition of BIOTRONIK's Vascular Intervention business for approximately EUR 760 million, and it has announced ~$2.03 billion in after-tax divestiture proceeds from selling its Acute Care, Interventional Urology, and OEM businesses (expected H2 2026). New CEO Jason Weidman joined from Medtronic on June 8, 2026, leading a multi-year restructuring targeting $48–52 million in annual pre-tax savings. The company has 50+ years of consecutive dividend payments and trades on NYSE under TFX, with activist investor Irenic Capital (~2%) and reported take-private interest from CVC Capital Partners and GTCR in April 2026.

Name

Teleflex

Legal name

Teleflex Incorporated

Website

https://teleflex.com

Company type

Public

Founded year

1943

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Teleflex Incorporated is a global medical technology company that designs and sells vascular access, interventional, surgical, urology, anesthesia, and emergency medicine devices to hospitals, EMS providers, and federal/military healthcare facilities worldwide, with FY2025 revenue of $1.99B.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

akta.pro secondary industries

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK), Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL), Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

Keywords

• Medical device manufacturing
• Vascular access products
• Interventional cardiology devices
• Surgical instruments supply
• Airway management devices

Headquarters

HQ city

Wayne

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Teleflex generates the majority of its revenue through the sale of medical devices, surgical instruments, vascular access products, and interventional solutions to hospitals and healthcare providers. Products are sold directly through sales representatives and through distribution channels. Revenue is primarily one-time purchase of capital equipment and consumable supplies, with some recurring revenue from service contracts and parts.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Teleflex designs, develops, manufactures, and sells a broad portfolio of single-use and reusable medical devices organized across Vascular Access, Anesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology, Surgical, Urology, and Military-Federal product areas. Its flagship lines include Arrow-branded antimicrobial and central venous catheters, the VPS catheter tip-positioning system, EZ-IO intraosseous access, the MANTA vascular closure device, Freesolve bioresorbable magnesium scaffold, UroLift and Barrigel urology products, Weck surgical ligation/closure systems, LMA airway devices, and QuikClot hemostatic dressings.

Product overview

Teleflex is a global provider of medical technologies organized into distinct product portfolios covering Vascular Access, Anesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology, Surgical, Urology, and Military-Federal markets. The company's core products include the Arrow-branded vascular access portfolio (Arrowg+ard antimicrobial catheters, VPS positioning systems, EZ-IO intraosseous systems), interventional devices (MANTA closure device, Freesolve resorbable scaffold, GuideLiner catheters, IABP), urology solutions (UroLift System, Barrigel, Rüsch catheters), surgical products (MiniLap, Weck ligation, EFx closure), and anesthesia/airway management (LMA airways, ISO-Gard mask). The portfolio is distributed across multiple product categories including central venous catheters, peripheral catheters, intermittent catheters, surgical instruments, and interventional devices, with key brands including Arrow, Rüsch, Weck, and LMA.

Differentiator

Problem solved

Functional benefit

Brands

• Arrow: Vascular access products including CVCs, PICCs, arterial catheters, and related accessories
• Rüsch
• Weck
• EZ-IO
• LMA
• QuikClot
• MANTA
• UroLift
• Barrigel

Products and services

• Arrowg+ard Blue Plus CVC Antimicrobial central venous catheter with chlorhexidine/silver sulfadiazine protection against gram-positive bacteria, gram-negative bacteria, and fungi. Provides complete coverage including extension lines, hub and catheter, used by hospitals to reduce catheter-related bloodstream infections.
• Arrow VPS Rhythm DLX Catheter tip positioning system combining Doppler ultrasound, intravascular ECG and algorithmic logic to position catheters in the lower 1/3 of the SVC/CAJ. FDA cleared to replace chest X-ray confirmation, reducing procedure time and radiation exposure for clinicians and patients.
• EZ-IO Intraosseous Vascular Access System Intraosseous vascular access system providing immediate access through bone for delivery of essential medications and fluids. Includes T.A.L.O.N. Needle Set and FAST1 Intraosseous Infusion System. Used by emergency departments, ICUs, EMS, and military medics when conventional IV access fails.
• Freesolve Resorbable Magnesium Scaffold Resorbable magnesium scaffold (DREAMS 3G) for treating narrowed arteries. Designed to resorb within 12 months, potentially reducing long-term complications associated with permanent metallic implants. Under evaluation in the BIOMAG clinical trial program targeting interventional cardiology approval.
• UroLift System Minimally invasive device for treating benign prostatic hyperplasia (BPH). Clinical data showed significantly better catheter independence (3% vs. 20% for Rezum) and preserved sexual function through 12 months. Acquired with the NeoTract acquisition in 2017.
• Barrigel Rectal Spacer Rectal spacer product for prostate cancer patients undergoing radiation therapy. Demonstrated sustained reduction in radiation-associated gastrointestinal toxicity with zero percent Grade 2+ toxicity over three years versus 10 percent in the control arm. Acquired with the Palette Life Sciences acquisition in 2023.
• MANTA Vascular Closure Device Vascular closure device for closure of femoral arterial access sites while reducing time to hemostasis following use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures, including TAVR and large-bore interventional cases.
• LMA Airways Supraglottic airway management devices for anesthesia and emergency medicine applications, including laryngeal mask airways used in operating rooms and emergency settings.
• MiniLap Percutaneous Surgical System Minimally invasive surgery product for percutaneous laparoscopy procedures, offering less traumatic access for surgeons performing laparoscopic procedures through smaller incisions.
• Weck Hem-o-lok Polymer Ligation System Polymer locking ligation system for surgical procedures, marketed as the standard in clip security for vessel and tissue ligation in laparoscopic and open surgery.
• Rüsch Intermittent Catheters Complete line of bladder management solutions including hydrophilic, uncoated, and closed system intermittent catheters, and Tiemann catheters for difficult catheterization, serving urology patients and intermittent self-catheterization users.
• Arrow OnControl Powered Bone Access System Bone marrow aspiration and biopsy system for the iliac crest of adult and pediatric patients, and bone lesion biopsy of vertebral body. Used by hematologists and interventional radiologists.
• Arrow AC3 Optimus IABP Intra-aortic balloon pump for acute coronary syndrome, cardiac/non-cardiac surgery, and heart failure complications, used in cardiac catheterization labs and cardiac surgery.
• GuideLiner V3 Catheter Guide catheter used in conjunction with standard guide catheters to access discrete regions of coronary and peripheral vasculature, facilitate placement of interventional devices, and assist in crossing chronic total occlusions (CTO) in complex PCI and peripheral interventions.
• EFx Shield Fascial Closure System Fascial closure system providing confidence and control in surgical closure procedures, particularly for laparoscopic port-site closure and bariatric surgery.
• QuikClot Combat Gauze Hemostatic dressings for military and emergency use, including QuikClot Combat Gauze which is the standard of care hemostatic gauze adopted by the U.S. military for battlefield hemorrhage control.

Quantifiable outcome

• Arrowg+ard Blue technology helps reduce catheter-related bloodstream infections in vascular access procedures
• +1 more outcomes

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered major, core and minor.

• BIOTRONIKmajorStrategic or Co-development PartnerTeleflex acquired BIOTRONIK's Vascular Intervention business, adding a portfolio of coronary and peripheral vascular devices to Teleflex's product offerings. This strategic acquisition enhances Teleflex's position in the interventional cardiology and vascular surgery markets.
• o9 SolutionscoreTechnology or IntegrationTeleflex partnered with o9 Solutions to implement their AI-powered demand planning and supply planning platform. This digital transformation initiative improves forecasting accuracy, supply chain efficiency, and inventory management across Teleflex's global operations.
• Premier Applied SciencesminorStrategic or Co-development PartnerTeleflex partnered with Premier Applied Sciences for real-world evidence (RWE) research collaborations. This partnership supports clinical research initiatives and generates evidence demonstrating the effectiveness and value of Teleflex medical devices in real-world clinical settings.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global medical device incumbent competing directly with Teleflex across vascular access, interventional cardiology (where Medtronic recently settled a catheter patent case against Teleflex), and peripheral vascular. Weidman, Teleflex's incoming CEO, joins from Medtronic.
• Boston Scientific: Major interventional cardiology and peripheral vascular incumbent; competes with Teleflex in coronary and peripheral vascular intervention post-BIOTRONIK acquisition.
• Edwards Lifesciences: Cardiovascular device incumbent; competes in adjacent structural heart and critical care monitoring categories, with overlap in hospital cardiac procedural markets.
• Stryker: Surgical instruments and operating-room equipment competitor, with overlap in the Weck ligation, MiniLap percutaneous laparoscopic, and surgical closure categories.

Direct peers

• Abbott: Direct competitor in interventional cardiology; its Xience DES is the comparator arm in Teleflex's BIOMAG-III pivotal trial of the Freesolve resorbable scaffold.
• Becton, Dickinson and Company (BD): Direct competitor in central venous catheters, PICCs, and vascular access consumables, competing head-to-head with the Arrow portfolio at hospital GPOs.
• ICU Medical: Direct competitor in vascular access (CVCs, PICC lines) and IV therapy after acquiring Smiths Medical, increasing scale and channel leverage against Teleflex's Arrow franchise.
• B. Braun: Global medical device competitor across vascular access (CVCs, PICC lines), surgical instruments, and anesthesia delivery — directly comparable to Teleflex's Arrow and LMA franchises.

Emerging players

• Penumbra: Interventional vascular specialist growing in peripheral vascular thrombectomy and coronary; competes with Teleflex's GuideLiner and BIOTRONIK-acquired peripheral vascular portfolio.
• Inari Medical: Emerging interventional specialist in venous thromboembolism and peripheral vascular; represents a fast-growing competitor to Teleflex's peripheral vascular franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/teleflex
• YouTubeyoutube.com/@TeleflexNA
• Facebookfacebook.com/Teleflex
• LinkedInlinkedin.com/company/teleflex

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A20 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teleflex